Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Androgen Independent Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00390468
What this trial is testing

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

Who this might be right for
Metastatic CancerPainProstate Cancer
National Cancer Institute (NCI) 18
Testing effectiveness (Phase 2)Study completedNCT00089609
What this trial is testing

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

Who this might be right for
Prostatic Neoplasms
National Cancer Institute (NCI) 73
Testing effectiveness (Phase 2)Ended earlyNCT00019695
What this trial is testing

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Stage IV Prostate CancerBone MetastasesAdenocarcinoma of the Prostate+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT00683475
What this trial is testing

IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

Who this might be right for
Prostate Cancer
Eli Lilly and Company 138
Testing effectiveness (Phase 2)Study completedNCT00121238
What this trial is testing

Cilengitide in Treating Patients With Prostate Cancer

Who this might be right for
Recurrent Prostate CancerStage I Prostate CancerStage IIA Prostate Cancer+2 more
National Cancer Institute (NCI) 16
Early research (Phase 1)Ended earlyNCT00096304
What this trial is testing

Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Medical University of South Carolina 36
Testing effectiveness (Phase 2)Study completedNCT00080678
What this trial is testing

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Who this might be right for
Metastatic CancerProstate Cancer
M.D. Anderson Cancer Center 116
Large-scale testing (Phase 3)Study completedNCT00065442
What this trial is testing

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Who this might be right for
Prostate Cancer
Dendreon 512
Testing effectiveness (Phase 2)Study completedNCT00195039
What this trial is testing

Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 47
Early research (Phase 1)Study completedNCT00113984
What this trial is testing

Vaccine and Antibody Treatment of Prostate Cancer

Who this might be right for
Prostatic Neoplasms
National Cancer Institute (NCI) 30
Large-scale testing (Phase 3)Study completedNCT00436839
What this trial is testing

Taxotere Prostate Cancer New Indication Registration Trial in China

Who this might be right for
Prostatic Neoplasms
Sanofi 228
Testing effectiveness (Phase 2)Study completedNCT00072930
What this trial is testing

MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

Who this might be right for
Prostate Cancer
MedImmune LLC 150
Testing effectiveness (Phase 2)Study completedNCT00459186
What this trial is testing

The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

Who this might be right for
Metastatic, Androgen Independent Prostate CancerProstate Cancer
Dana-Farber Cancer Institute 19
Testing effectiveness (Phase 2)Study completedNCT00814788
What this trial is testing

Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
University of California, Davis 24
Testing effectiveness (Phase 2)Study completedNCT00574769
What this trial is testing

Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer

Who this might be right for
Prostate Cancer
University of Southern California 27
Early research (Phase 1)Study completedNCT00038194
What this trial is testing

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center 28
Testing effectiveness (Phase 2)Ended earlyNCT00753220
What this trial is testing

Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer

Who this might be right for
Prostate Cancer
Bostwick Laboratories 7
Testing effectiveness (Phase 2)Study completedNCT00083005
What this trial is testing

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate

Who this might be right for
Prostate Cancer
National Institutes of Health Clinical Center (CC) 60
Testing effectiveness (Phase 2)Study completedNCT01487863
What this trial is testing

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer MetastaticHormone Refractory Prostate CancerCastration-resistant Prostate Cancer
Dendreon 69
Testing effectiveness (Phase 2)Study completedNCT00258284
What this trial is testing

Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Barbara Ann Karmanos Cancer Institute 30
Next Page